Carlson Capital L P Cue Biopharma, Inc. Transaction History

Carlson Capital L P

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.77 - $3.09 $177,000 - $309,000	-100,000 Reduced 83.33%	20,000 $37,000
Q4 2023 Feb 13, 2024	SELL	$1.72 - $3.1 $25,800 - $46,500	-15,000 Reduced 11.11%	120,000 $316,000
Q3 2023 Nov 13, 2023	BUY	$2.23 - $4.69 $2,149 - $4,521	964 Added 0.72%	135,000 $310,000
Q2 2023 Aug 10, 2023	SELL	$3.11 - $4.91 $373,200 - $589,200	-120,000 Reduced 47.24%	134,036 $489,000
Q1 2023 May 12, 2023	SELL	$2.41 - $3.74 $267,423 - $415,005	-110,964 Reduced 30.4%	254,036 $906,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $406,300 - $671,500	-170,000 Reduced 31.78%	365,000 $1.04 Million
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $100,350 - $151,650	-45,000 Reduced 7.76%	535,000 $1.19 Million
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $435,750 - $1.04 Million	175,000 Added 43.21%	580,000 $1.44 Million
Q1 2022 May 13, 2022	BUY	$4.41 - $12.28 $948,150 - $2.64 Million	215,000 Added 113.16%	405,000 $1.98 Million
Q4 2021 Feb 11, 2022	BUY	$10.86 - $17.85 $946,818 - $1.56 Million	87,184 Added 84.8%	190,000 $2.15 Million
Q3 2021 Nov 12, 2021	SELL	$10.06 - $15.3 $481,713 - $732,625	-47,884 Reduced 31.77%	102,816 $1.5 Million
Q2 2021 Aug 13, 2021	SELL	$10.9 - $14.53 $42,510 - $56,667	-3,900 Reduced 2.52%	150,700 $1.76 Million
Q1 2021 May 13, 2021	BUY	$11.2 - $16.09 $779,520 - $1.12 Million	69,600 Added 81.88%	154,600 $1.89 Million
Q4 2020 Feb 12, 2021	BUY	$11.12 - $16.4 $945,199 - $1.39 Million	85,000 New	85,000 $1.06 Million

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.